Latest Breaking News On - Ben atwell - Page 16 : comparemela.com

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13).

Hong kongZhou yiBen atwell alex shawLiansheng zhangElsevier saundersFausto nelsonFengkui zhangCotran ramziPanmure gordonAnnie chengKumar vinayBing hanAtholl tweedie freddy crossleyNelso faustoMark leeAbbas abulk robbins

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongZhou yiBen atwell alex shawLiansheng zhangElsevier saundersFausto nelsonFengkui zhangCotran ramziPanmure gordonAnnie chengKumar vinayBing hanAtholl tweedie freddy crossleyNelso faustoMark leeAbbas abulk robbins

BenevolentAI Analyst / Investor Event

Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, announces that during its analyst investor event

New yorkUnited statesCity ofUnited kingdomFoster mitchellBen atwellSimon conwayRajin kang vp communicationsCompany euronext amsterdamRegulatory newsEuronext amsterdamBenevolent platformVictoria foster mitchell

BenevolentAI : Inside Information / Ad Hoc Information - Analyst/Investor and Interim Results Presentation - new information in relation to Company s BEN-2293 Phase 1b Study Results - EN

BenevolentAI Analyst / Investor Event London, UK, 27 September 2022: BenevolentAI , a. | September 27, 2022

New yorkUnited statesUnited kingdomCity ofNoord hollandFoster mitchellRajin kangBen atwellSimon conwayFleur woodVp communicationsCompany euronextInvestor eventVictoria foster mitchellEuronext amsterdamBenevolent platform

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesIsrael generalHong kongFrance generalSouth koreaCity ofUnited kingdomComunidad autonoma de catalunaZhou yiAtholl tweedie freddy crossleyTakayuki yoshinoBen atwell alex shawMark leeEllenf kniselyArvind dasari